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Abstract
EuropeanexpertsonautoimmuneType 1diabetesmetfor2 daysinOctober2010inCambridge,toreviewthestate-of-the-art
and to discuss strategies for prevention of Type 1 diabetes (http:⁄⁄www- gene.cimr.cam.ac.uk⁄todd⁄sub_pages⁄T1D_
prevention_Cambridge_workshop_20_21Oct2010.pdf). Meeting sessions examined the epidemiology of Type 1 diabetes;
possibleunderlyingcausesofthecontinuingandrapidincreaseinType 1diabetesincidenceatyoungerages;andlessonslearned
from previous prevention trials. Consensus recommendations from the meeting were:
1. Resources such as national diabetes registries and natural history studies play an essential role in developing and reﬁning
assays to be used in screening for risk factors for Type 1 diabetes.
2. It is crucial to dissect out the earliest physiological events after birth, which are controlled by the susceptibility genes now
identiﬁed in Type 1 diabetes, and the environmental factors that might affect these phenotypes, in order to bring forward a
mechanistic approach to designing future prevention trials.
3. Current interventions at later stages of disease, such as in newly diagnosed Type 1 diabetes, have relied mainly on non-
antigen-speciﬁc mechanisms. For primary prevention—preventing the onset of autoimmunity—interventions must be based
on knowledge of the actual disease process such that: participants in a trial would be stratiﬁed according the disease-
associated molecular phenotypes; the autoantigen(s) and immune responses to them; and the manipulation of the
environment, as early as possible in life. Combinations of interventions should be considered as they may allow targeting
different components of disease, thus lowering side effects while increasing efﬁcacy.
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Type 1 diabetes occurs when the body’s immune system turns
against itself so that, in a very speciﬁc and targeted way, it
destroysthepancreaticisletb-cells,theonlycellsinthebodythat
producethevitalhormoneinsulin.Thisautoimmunedestruction
is irreversible and the disease incurable. If new pancreas or islets
are transplanted they too are destroyed, unless heavy
immunosuppression is applied. Recent genetics and
mechanistic studies in humans are indicating major pathways
that play roles in early disease development, especially in the
interleukin-2 (IL-2) and type 1 interferon systems, probably in
concert with the immune response to preproinsulin [1,2].
Longitudinal studies of children born with high genetic risk of
Type 1 diabetes showed that circulating autoantibodies to islet
antigens can be seen as early as 6 months. A large proportion of
childhood cases hasseroconverted by age 3 years,and almostall
cases by age 7 years, even although median age-at-diagnosis is
approximately12 years[3,4].Childrenwhowillgoontodevelop
Type 1 diabetes in the future must be born with the ﬁrst
precursors of the disease. A child aged under age 5 years with a
familyhistoryofType 1diabetes,carryingthehighestriskhuman
leukocyte antigen (HLA) class II genotypes and persistently
positive for two or more autoantibody types, has a more than
90% chance of being diagnosed with the disease [5]. By making
the connection between gene variant and phenotype, genetics
provides a way to identify pathways leading to Type 1 diabetes,
including the earliest physiological events after birth, and the
earliest events in the disease process, including clues about what
may be environmental factors or accelerators of disease [4,6].
National diabetes registries, especially those with available
biosamples, provide Europe with important population-based
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testing hypotheses about disease initiation and progression.
Registrydatawhereavailableprovideevidencethattheincidence
of Type 1 diabetes in children under age 15 years has increased.
However, there is a shortage of data on Type 1 diabetes over
age 15, although at least half of new cases occur after age 15.
Data from registries should be accessible to all bona ﬁde
researchers, provided that necessary conﬁdentiality protections
areinplace.Commonstandardsregardingdataﬁeldswouldadd
value and also aid data access.
The appearance of autoantibodies, the ﬁrst of which
chronologically are usually against insulin itself, is a secondary
or downstream event in the autoimmune process. Identiﬁcation
and validation of biomarkers that precede autoantibody
appearance are urgently required. Incentives to provide access
to these collections should be implemented [7]. Useful
information to provide possible investigators with includes
limitations of the informed consent, types and amounts of
material available and storage conditions. Efforts should be
made to extend collections of samples of at-risk individuals and
persons with newly diagnosed diabetes. Funding opportunities
should be implemented to encourage investigators to develop
assays that could be used retrospectively, to employ new
technologies and to use smaller assay volumes for studying
markers.
Despite the limited success of previous prevention trials, they
have provided valuable lessons, combined with correctly
interpreted data from the animal models. Predictions of the
natural history of disease based on combined genetic (HLA) and
serological markers (autoantibodies) are accurate. C-peptide is a
surrogate marker for loss of b-cell function and progression to
diabetes; and the oral glucose tolerance test is a sensitive
screening tool for detecting individuals with diabetes before
fastingbloodsugarorHbA1clevelsbecomeabnormal.Screening
for risk of diabetes can avoid suffering in children, as diabetic
ketoacidosis prevalence was 4% in children enrolled in
prevention trials compared with 15–20% in new-onset
children in the general population [8]. Interventions at later
stages of disease, such as in newly diagnosed Type 1 diabetes,
have used mainly non-antigen-speciﬁc drugs, with the promising
studies having used doses at the edge of safety. Successfully
preventingtheonsetofautoimmunity—trueprimaryprevention—
must include antigen-speciﬁc tolerance approaches [2]. It is
importanttobeginnowtoaccuratelyestablishdoses,timingand
best route of administration, whilst analysing mechanistic
effects.
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